Introduction {#s1}
============

Bladder cancer is the most common malignant tumor of the urinary system. According to the International Agency for Research on Cancer for 2008, about 386,300 individuals were diagnosed with bladder cancer and 150,200 died as a result. The majority of bladder cancer occurs in males and the highest incidence rates are found in the countries of Europe, North America, and Northern Africa [@pone.0070008-Jemal1]. In the US, bladder cancer is the fourth most common cause of cancer among men and the ninth most common cause of cancer death among men [@pone.0070008-Siegel1]. The overall public health importance of bladder cancer is increasing with the growing elderly population.

Cigarette smoking and occupational exposures are the main risk factors for bladder cancer in Western countries, whereas chronic infection with Schistosoma hematobium in developing countries accounts for about 50% of the total burden [@pone.0070008-Parkin1]. Other environmental factors, including selenium intake [@pone.0070008-Zeegers1], chlorination by-products [@pone.0070008-Villanueva1] and low dose arsenic levels in drinking water [@pone.0070008-Guo1], have also been associated with bladder cancer, but are less well-established.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most frequently used drugs worldwide. Experimental and epidemiologic evidence strongly suggests that aspirin and non-aspirin NSAIDs have shown promise as chemopreventive agents [@pone.0070008-Harris1]. Most epidemiologic studies have reported inverse associations between NSAIDs use and the risk of breast [@pone.0070008-Luo1], gastric [@pone.0070008-Tian1], and colorectal cancer [@pone.0070008-Rostom1]. However, whether NSAIDs use may reduce the risk of bladder cancer remains unclear. There have been few meta-analyses of NSAIDs use and cancer risk in general, which included some studies of bladder cancer and did not exclusively focus on this disease [@pone.0070008-Bosetti1]. The effect of NSAIDs on the risk of bladder cancer remains to be determined. Therefore, we conducted a comprehensive meta-analysis of studies exclusively dedicated to the relationship between the 3 most commonly used analgesics and bladder cancer risk.

Materials and Methods {#s2}
=====================

Search Strategy {#s2a}
---------------

A systematic literature search up to November 1 of 2012 was performed in PubMed database to identify eligible studies. Search terms included "acetaminophen," "aspirin," "nonsteroidal anti-inflammatory agents," or "NSAID" combined with "bladder cancer," "bladder neoplasms," or "bladder carcinoma". The titles and abstracts of the studies identified in the search were scanned to exclude any clearly irrelevant studies. The full texts of the remaining articles were read to determine whether they contained information on the topic of interest. Furthermore, we also manually searched the reference lists of every article retrieved and review papers to find any additional published studies. All searches were conducted independently by 2 authors (HZ and DJ). The results were compared, and any questions or discrepancies were resolved through iteration and consensus.

Study Selection {#s2b}
---------------

To be eligible, studies had to fulfill the following 4 inclusion criteria: 1) had a case-control or prospective study design; 2) reported results on aspirin, non-aspirin NSAIDs or acetaminophen use; 3) the outcome was bladder cancer incidence or mortality; and 4) reported the estimate of relative risk (RR) with their corresponding 95% confidence interval (CI) (or sufficient data to calculate of these effect measure). Studies reporting different measures of RR like risk ratio, rate ratio, hazard ratio (HR), and odds ratio (OR) were included in the meta-analysis. In practice, these measures of effect yield a similar estimate of RR, since the absolute risk of bladder cancer is low.

Data Extraction {#s2c}
---------------

Data abstraction was conducted independently by 2 researchers (HZ and DJ), with disagreements resolved by consensus. The following information were collected: the first author's last name, year of publication, country in which the study was performed, study design, years of follow-up or the study period, study participants age range, number of subjects and number of bladder cancer cases, used drugs, exposure definition, information source, control of confounding factors by matching or adjustment, and RR estimates with corresponding 95% CIs. If a study provided several risk estimates, the most completely adjusted estimate was extracted. Differences in data extraction were resolved by consensus, referring back to the original article.

Statistical analysis {#s2d}
--------------------

Separate analyses were performed according to use of acetaminophen, aspirin, and non-aspirin NSAIDs. Study-specific risk estimates were extracted from each article, and log risk estimates were weighted by the inverse of their variances to obtain a pooled risk estimate. We pooled study-specific log RRs to compute an overall RR and its 95% CI for regular/any use versus reference group from each study. For reference group, it was defined as "subjects who never took analgesics or who were not regular takers". Where data for different intake levels or different duration of use were available, we subsequently restricted the analyses to the highest intake or the longest duration given by each study. Studies were combined by using the DerSimonian and Laird random-effects model, which considers both within- and between-study variations [@pone.0070008-DerSimonian1].

Statistical heterogeneity among studies was assessed using the Cochrane's Q statistic, and inconsistency was quantified with the *I^2^* statistic that estimates the percentage of total variation across studies due to heterogeneity rather than chance [@pone.0070008-Higgins1]. For the Q statistic, a *P* value \<0.10 was considered statistically significant for heterogeneity; for *I^2^*, a value \>50% is considered a measure of severe heterogeneity. When statistical heterogeneity was detected, sensitivity analyses were performed. Publication bias was evaluated with Egger's regression test in which *P* value less than 0.10 was considered representative of statistically significant publication bias [@pone.0070008-Egger1]. All statistical analyses were performed with Stata 10 software (Stata Corporation, College Station, Texas). We performed this meta-analysis in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement [@pone.0070008-Moher1].

Results {#s3}
=======

Literature Search {#s3a}
-----------------

The detailed steps of our literature search are shown in [Figure 1](#pone-0070008-g001){ref-type="fig"}. Briefly, our initial search strategy retrieved a total of 363 citations. After the titles and abstracts were screened, 339 articles were excluded because they were laboratory studies, review articles, or irrelevant to the current study. We identified 24 potentially relevant articles. Three articles were excluded because they reported on similar population [@pone.0070008-Schreinemachers1]--[@pone.0070008-Jacobs1]. Two publications were excluded because there were no outcomes of bladder cancer [@pone.0070008-Steineck1], [@pone.0070008-Rosenberg1], one was excluded because it did not provide RR estimate [@pone.0070008-PaganiniHill1] and the remaining one was excluded because it did not report analgesics use of our interest [@pone.0070008-Langman1]. Finally, 17 articles [@pone.0070008-Piper1]--[@pone.0070008-Baris1] were included in this meta-analysis ([Figure 1](#pone-0070008-g001){ref-type="fig"}).

![Flow diagram of study identification.](pone.0070008.g001){#pone-0070008-g001}

The 17 relevant studies were published between 1985 and 2012, including 8 cohort studies [@pone.0070008-Friis1]--[@pone.0070008-Ratnasinghe1], [@pone.0070008-Genkinger1]--[@pone.0070008-Shih1] and 9 case-control studies [@pone.0070008-Piper1]--[@pone.0070008-Kaye1], [@pone.0070008-Blumentals1]--[@pone.0070008-Fortuny2], [@pone.0070008-Baris1]. A total of 1,008,800 participants, including 10,618 bladder cancer cases were involved in these studies and followed for 3--21 years. Ten studies were used for analysis of acetaminophen use [@pone.0070008-Piper1]--[@pone.0070008-Friis1], [@pone.0070008-Fortuny1]--[@pone.0070008-Genkinger1], [@pone.0070008-Baris1], 11 for aspirin use [@pone.0070008-Pommer1], [@pone.0070008-Castelao1], [@pone.0070008-Friis2], [@pone.0070008-Ratnasinghe1], [@pone.0070008-Fortuny1]--[@pone.0070008-Baris1] and 6 for non-aspirin NSAIDs use [@pone.0070008-Srensen1], [@pone.0070008-Blumentals1], [@pone.0070008-Fortuny1], [@pone.0070008-Daugherty1], [@pone.0070008-Shih1], [@pone.0070008-Baris1]. The characteristics of the included studies for the 3 most commonly used analgesics are summarized in [Table 1](#pone-0070008-t001){ref-type="table"}. Most studies provided risk estimates that were adjusted for age (16 studies), sex (14 studies) and smoking (12 studies); fewer were adjusted for race (6 studies), body mass index (4 studies), and education (4 studies). The exposure definitions of the included studies are shown in [Table 2](#pone-0070008-t002){ref-type="table"}.

10.1371/journal.pone.0070008.t001

###### Characteristics of studies included in the meta-analysis.

![](pone.0070008.t001){#pone-0070008-t001-1}

  Study               Year   Country   Design   Studyperiod   Age, y   N. ofparticipant   BC Cases        Drug(s)        Informationsource   Adjustments[\*](#nt102){ref-type="table-fn"}
  ------------------ ------ --------- -------- ------------- -------- ------------------ ---------- ------------------- ------------------- ----------------------------------------------
  Piper (23)          1985     USA      C-C     1975--1979    20--49         173            173             ACE              Interview                           1--3
  Derby (24)          1996     USA      C-C     1980--1991     ≥20          2,009           504             ACE              Database                         1, 2, 4, 5
  Pommer (25)         1999   Germany    C-C     1990--1994     70.4          921            571           ACE/ACA            Interview                         1, 6--8
  Castelao (26)       2000     USA      C-C     1987--1996    25--74         1514           1514          ACE/ACA            Interview                      1, 2, 6, 9, 10
  Kaye (27)           2001     USA      C-C     1995--1998     \>50          187            744             ACE              Database                  1, 2, 6, 11, 12, 13, 14
  Friis (28)          2002   Denmark     Co     1989--1995      63          39,946          115             ACE              Database                            1, 2
  Friis (29)          2003   Denmark     Co     1989--1997      70          29,470          161             ASA              Database                            1, 2
  Sørensen (30)       2003   Denmark     Co     1989--1995     47.2        172,057          330          NA-NSAIDs           Database                            1, 2
  Ratnasinghe (31)    2004     USA       Co     1971--1992    25--74        22,843           40             ASA              Interview                    2, 6,7, 9, 14, 15,
  Blumentals (32)     2004     USA      C-C     1992--1994     71.1         1,293           330          NA-NSAIDs           Database                        1, 2, 6, 16
  Fortuny(33)         2006    Spain     C-C     1997--2000    20--80        1,029           958      ACE/ACA/NA-NSAIDs       Interview                      1, 2, 3, 6, 16
  Fortuny (34)        2007     USA      C-C     1998--2001    25--74         463            376           ACE/ACA            Interview                       1, 2, 6, 16
  Genkinger (35)      2007     USA       Co     1986--2004    40--75        49,448          607           ACE/ACA          Questionnaire                   1, 3, 6, 17, 18
  Daugherty (36)      2011     USA       Co     1993--2005     62.1        508,842         2,489       ASA/NA-NSAIDs       Questionnaire                    6, 14--16, 19
  Jacobs (37)         2012     USA       Co     1997--2008      NR         100,139          150             ASA            Questionnaire             1, 2, 6, 9, 14--16, 20-- 26
  Shih (38)           2012     USA       Co     2000--2010    50--76        77,048          385        ASA/NA-NSAIDs       Questionnaire                1, 2, 6, 9, 15, 16, 27
  Baris (39)          2013     USA      C-C     2001--2004    30--79        1,418          1,171     ACE/ACA/NA-NSAIDs       Interview                    1, 2, 3, 6, 15, 28

Abbreviations: BC, bladder cancer; C-C, case control; Co, cohort; NR, not reported; ACE: Acetaminophen; ASA: aspirin; NA-NSAIDs: nonaspirin NSAIDs.

1, age; 2, sex; 3, residence; 4, certain occupations; 5, coffee drinking; 6, smoking; 7, socioeconomic status; 8, laxative intake, 9, education; 10, number of years employed as hairdresser/barber, 11, general practice; 12, duration of prescription history in the database; 13, index date; 14, body mass index, 15, race; 16, analgesic use; 17, period;18, fluid intake; 19, study; 20, physical activity; 21, history of heart disease; 22, stroke; 23, diabetes; 24, hypertension; 25, cholesterol-lowering drug use; 26, history of colorectal endoscopy; 27, family history of bladder cancer; 28, Hispanic status.

10.1371/journal.pone.0070008.t002

###### Exposure definition in each study.

![](pone.0070008.t002){#pone-0070008-t002-2}

  Study                                      Exposure definition
  ------------------ -------------------------------------------------------------------
  Piper (23)          Regular use (daily use for at least 30 days per year) vs. no use
  Derby (24)                  Any use (≥1 prescription in past year) vs. no use
  Pommer (25)           Regular use (lifelong cumulative amount of ≥1 kg) vs. no use
  Castelao (26)        Regular use (≥2 times a week for ≥1 month) vs. no/irregular use
  Kaye (27)                         Any use (≥1 prescription) vs. no use
  Friis (28)                         Any use(≥1 prescription) vs. no use
  Friis (29)           Regular use low-dose aspirin (75--150 mg once daily) vs. no use
  Sørensen (30)                     Any use (≥1 prescription) vs. no use
  Ratnasinghe (31)    Any use (use any aspirin in past 30 days or 6 months ) vs. no use
  Blumentals (32)                   Any use (≥1 prescription) vs. no use
  Fortuny(33)               Regular use (≥2 times a week for ≥1 month) vs. no use
  Fortuny (34)              Regular use (≥4 times a week for ≥1 month) vs. no use
  Genkinger (35)                  Regular use (≥2 times a week) vs. no use
  Daugherty (36)                  Regular use (\>2 times a week) vs. no use
  Jacobs (37)                        Regular use (daily use) vs. no use
  Shih (38)                 Regular use (\>1 tine a week for ≥1 year) vs. no use
  Baris (39)                Regular use (≥2 times a week for ≥1 month) vs. no use

Acetaminophen {#s3b}
-------------

The multivariable-adjusted RRs of bladder cancer for regular/any use of acetaminophen in individual observational studies and summary estimate are shown in [Figure 2](#pone-0070008-g002){ref-type="fig"}. Regular/any use of acetaminophen was not associated with the risk of bladder cancer (RR 1.01, 95% CI 0.88--1.17). The Cochran's Q test resulted in a *P* = 0.38 (Q = 9.70), and the corresponding quantity *I^2^* was 7.3%, both indicating that the results of those studies were homogeneous. The *P* value for the Egger test was *P* = 0.23, suggesting a low probability of publication bias. The associations of acetaminophen use with bladder cancer risk did not differ by study type ([Table 3](#pone-0070008-t003){ref-type="table"}).

![Risk estimates of bladder cancer associated with regular/any use of acetaminophen.\
Squares indicate study-specific risk estimates (size of the square reflects the study-specific statistical weight, i.e., the inverse of the variance); horizontal lines indicate 95% confidence intervals (CIs); diamonds indicate summary risk estimate with its corresponding 95% confidence interval.](pone.0070008.g002){#pone-0070008-g002}

10.1371/journal.pone.0070008.t003

###### Summary risk estimates.

![](pone.0070008.t003){#pone-0070008-t003-3}

  Stratification group             References           RR (95% CI)   Heterogeneity test                    
  ----------------------- ---------------------------- ------------- -------------------- ------- --------- ------
  Acetaminophen                                                                                             
  Regular/any use              23--28, 33--35, 39          1.01           0.88--1.17       9.70     0.375    7.3
  Case-control studies         23--27, 33, 34, 39          0.99           0.82--1.20       9.46     0.221    26.0
  Cohort studies                     28, 35                0.97           0.70--1.34       0.08     0.773     0
  High intake                  24, 26--28, 33, 39          1.08           0.81--1.44       3.98     0.552     0
  Long duration                    33, 34, 39              0.80           0.43--1.48       3.53     0.171    43.4
  US                       23, 24, 26, 27, 34, 35, 39      1.01           0.82--1.23       8.63     0.195    30.5
  Europe                            25,28,33               0.92           0.68--1.25       0.45     0.800     0
  Aspirin                                                                                                   
  Regular/any use            25, 26, 29, 31, 33--39        1.02           0.91--1.14       19.49    0.035    48.7
  Case-control studies         25, 26, 33, 34, 39          0.95           0.76--1.18       9.94     0.042    59.7
  Cohort studies                 29, 31, 35--38            1.06           0.93--1.20       8.51     0.130    41.2
  High intake                26, 33, 35, 36, 38, 39        0.96           0.83--1.12       7.04     0.218    29.0
  Long duration                  33, 34, 37, 39            1.04           0.82--1.32       0.93     0.819     0
  Men                               29,31,36               1.10           0.99--1.21       2.08     0.354    3.7
  Women                             29,31,36               1.43           0.68--3.00       13.12    0.001    84.8
  No smoker                        35, 36, 38              0.90           0.75--1.09       0.24     0.885     0
  Current smoker                   35, 36, 38              0.99           0.81--1.21       0.04     0.982     0
  US                             26, 31, 34--39            0.97           0.84--1.12       16.06    0.025    56.4
  Europe                           25, 29, 33              1.16           0.99--1.33       0.83     0.662     0
  Non-aspirin NSAIDs                                                                                        
  Regular/any use            30, 32, 33, 36, 38, 39        0.87           0.73--1.05       24.19   \<0.001   79.3
  Case--control studies            32, 33,39               0.76           0.62--0.95       3.19     0.203    37.3
  Cohort studies                   30, 36, 38              0.98           0.78--1.22       11.87    0.003    83.1
  No smoker                        32, 36, 38              0.57           0.43--0.76       0.04     0.979     0
  Current smoker                     36, 38                1.24           0.63--2.46       2.31     0.129    56.7
  US                             32, 36, 38, 39            0.86           0.79--0.94       2.19     0.534     0
  Europe                             30, 33                0.74           0.25--2.15       7.96     0.005    87.4

Abbreviation: RR, relative risk; CI, confidence intervals.

*I^2^* is interpreted as the proportion of total variation across studies that are due to heterogeneity rather than chance.

Further, six studies [@pone.0070008-Derby1], [@pone.0070008-Castelao1]--[@pone.0070008-Friis1], [@pone.0070008-Fortuny1], [@pone.0070008-Baris1] were reported RR estimates of the association between high intake of acetaminophen and bladder cancer risk ([Table 3](#pone-0070008-t003){ref-type="table"}). Based on the results from those studies, the calculated combined RR for bladder cancer in high intake of acetaminophen was found to be 1.08 (95% CI 0.81--1.44). And the association was also not significant (RR 0.80, 95% CI 0.43--1.48) with long duration of acetaminophen use among limited number of studies with that available information [@pone.0070008-Fortuny1], [@pone.0070008-Fortuny2], [@pone.0070008-Baris1]. Stratified analysis by country did not show any statistically significant difference in summary estimates between strata.

Aspirin {#s3c}
-------

The multivariable-adjusted RRs of bladder cancer for regular/any use of aspirin in individual observational studies and summary estimate are shown in [Figure 3](#pone-0070008-g003){ref-type="fig"}. The pooled RR of bladder cancer for regular/any aspirin use was 1.02 (95% CI 0.91--1.14). There was statistically significant heterogeneity among studies (*P = *0.035, *I^2^* = 48.7%). The Egger test showed no evidence of publication bias for aspirin (*P = *0.686). The associations of aspirin use with bladder cancer risk did not differ by study type ([Table 3](#pone-0070008-t003){ref-type="table"}).

![Risk estimates of bladder cancer associated with regular/any use of aspirin.\
Squares indicate study-specific risk estimates (size of the square reflects the study-specific statistical weight, i.e., the inverse of the variance); horizontal lines indicate 95% confidence intervals (CIs); diamonds indicate summary risk estimate with its corresponding 95% confidence interval.](pone.0070008.g003){#pone-0070008-g003}

To explore the heterogeneity among studies of aspirin use and bladder cancer, we performed sensitivity analyses. By using a stepwise process, we determined that most of heterogeneity was accounted for the study by Fortuny et al [@pone.0070008-Fortuny2]. After excluding this single study, there was no study heterogeneity (*P = *0.20, *I^2^* = 26.4%), and the RR was essentially unchanged (RR 1.05, 95% CI 0.96--1.15).

High intake or long duration of aspirin use was also not associated with bladder cancer risk ([Table 3](#pone-0070008-t003){ref-type="table"}). In addition, stratified analysis by smoking status, gender and country did not show any statistically significant difference in summary estimates between strata.

Non-aspirin NSAIDs {#s3d}
------------------

Six studies [@pone.0070008-Srensen1], [@pone.0070008-Blumentals1], [@pone.0070008-Fortuny1], [@pone.0070008-Daugherty1], [@pone.0070008-Shih1], [@pone.0070008-Baris1] were reported RR estimates of the association between non-aspirin NSAIDs use and bladder cancer risk ([Figure 4](#pone-0070008-g004){ref-type="fig"}). No association was observed between regular/any non-aspirin NSAIDs use and the risk of bladder cancer (RR 0.87, 95% CI 0.73--1.05). There was statistically significant heterogeneity among studies (*P*\<0.001, *I^2^* = 79.3%). The Egger test showed no evidence of publication bias for aspirin (*P = *0.118). And we found that non-aspirin NSAIDs use was statistically significantly associated with reduced risk of bladder cancer among case-control studies, but not among cohort studies ([Table 3](#pone-0070008-t003){ref-type="table"}).

![Risk estimates of bladder cancer associated with regular/any use of non-aspirin NSAIDs.\
Squares indicate study-specific risk estimates (size of the square reflects the study-specific statistical weight, i.e., the inverse of the variance); horizontal lines indicate 95% confidence intervals (CIs); diamonds indicate summary risk estimate with its corresponding 95% confidence interval.](pone.0070008.g004){#pone-0070008-g004}

To explore the heterogeneity, we also performed the sensitivity analyses. By using a stepwise process, we determined that most of heterogeneity was accounted for the study by Sørensen et al [@pone.0070008-Srensen1]. After excluding this single study, there was no study heterogeneity (*P = *0.19, *I^2^* = 34.7%), and a significant association was observed (RR 0.83, 95% CI 0.74--0.94).

In addition, stratified analysis by smoking status found that non-aspirin NSAIDs use was statistically significantly associated with 43% reduced risks of bladder cancer among nonsmokers (RR 0.57; 95% CI, 0.43--0.76), but not among current smokers (RR 1.24; 95% CI, 0.63--2.46) ([Table 3](#pone-0070008-t003){ref-type="table"}). And we found that non-aspirin NSAIDs use was statistically significantly associated with reduced risk of bladder cancer among studies from the US, but not among studies from Europe.

Discussion {#s4}
==========

This present meta-analysis included 17 studies (8 cohort and 9 case-control studies), involving a total of 10,618 bladder cancer cases. In this meta-analysis of the 3 most commonly used analgesics and bladder cancer risk, we found that acetaminophen and aspirin were not associated with bladder cancer risk. Although non-aspirin NSAIDs was statistically significantly associated with reduced risk of bladder cancer among case-control studies (but not cohort studies), the overall risk was not statistically significant. Also, non-aspirin NSAIDs was significantly associated with a 43% reduction in bladder cancer risk among nonsmokers.

We found that acetaminophen use was not associated with the risk of bladder cancer with a pooled RR = 1.01 from 10 studies. Acetaminophen is a metabolite of phenacetin, a well-known banned carcinogen which has been more so linked to renal pelvic tumor [@pone.0070008-Clissold1]. Recently, a meta-analysis found that acetaminophen use was associated with 21% reduced risk of kidney cancer and the risk was higher with higher intake. In this meta-analysis, we did not found the associations of long term and high dose of acetaminophen use with bladder cancer risk.

In our meta-analysis, we did not found that aspirin use was associated with bladder cancer risk from 11 studies. Our results are in agreement with a large randomized controlled trial [@pone.0070008-Cook1]. In the Women's Health Study, low dose aspirin (100 mg every other day) for an average of ten years did not lower bladder cancer incidence. And in the meta-analysis of aspirin and cancer risk, the pooled risk for bladder cancer was 0.95 (95% CI 0.83--1.07) [@pone.0070008-Bosetti1].

We found from 6 studies that non-aspirin NSAIDs use was not associated with the risk of bladder cancer in general. Nevertheless, there was significant heterogeneity by study. After excluding the study by Sørensen et al [@pone.0070008-Srensen1], a significant inverse association was found. In this record linkage study from Denmark with 330 bladder cancer cases, prescribed non-aspirin NSAIDs slightly increased the risk of bladder cancer (RR 1.2; 95% CI, 1.0--1.3), although no dose-response relationship was observed. Misclassification is likely in studies relying solely on prescription data as many commonly used NSAIDs do not require a prescription. Therefore, due to the limited published information and relatively small number of cases, we still cannot draw the firm conclusion about non-aspirin NSAIDs use and bladder cancer risk. Further studies with a larger number of subjects may be able to discriminate the effects of specific NSAIDs more clearly.

Furthermore, an interest finding in our meta-analysis, although more limited, is that smoking status might modify the association of use of nonaspirin NSAIDs with bladder cancer risk. Smoking is a well-known risk factor for bladder cancer. There are over 60 carcinogens, including nitrosamines, aromatic amines, and polycyclic aromatic hydrocarbons, have been detected in cigarette smoke. Metabolic activation of these carcinogens leads to the formation of DNA adducts, causing miscoding and other mutations [@pone.0070008-Pfeifer1]. While smokers have been shown to have increased cycloxygenase (COX)-2 expression and activity in their urothelial tissues [@pone.0070008-Badawi1], it may be that the anticarcinogenic effects of nonaspirin NSAIDs against COX-2 are overwhelmed by the carcinogenic effects of smoking. Thus, a decrease in bladder cancer risk associated with nonaspirin NSAIDs has been shown in nonsmokers in our meta-analysis.

Our study has several strengths: it is the most up-to-date comprehensive review of analgesics on one specific type of cancer, bladder cancer. It includes the 3 mostly used contemporary drugs and 17 observational studies were included in our meta-analysis, reporting data of more than 1 million participants, including 10,618 bladder cancer patients. Meta-analysis of studies with large numbers of incident cases provides high statistical power for estimating the relationship between exposure and outcome risk. Moreover, in a meta-analysis of published studies, publication bias could be of concern since small studies with null results tend not to be published. In this meta-analysis, however, we found little evidence of publication bias.

Nevertheless, several limitations are worth mentioning. First, a meta-analysis is not able to solve problems with confounding factors that could be inherent in the included studies. Inadequate control for confounders may bias the results in either direction, toward exaggeration or underestimation of risk estimates. However, most observational studies in this meta-analysis adjusted for other known and potential risk factors for bladder cancer. Second, heterogeneity may be introduced because of methodologic and demographic differences among studies. We used appropriate well-motivated inclusion criteria to maximize homogeneity, and performed sensitivity and subgroup analyses to investigate potential sources of heterogeneity. Third, studies used different definition of analgesic use, which might have limited comparability of the results across the studies. However, our findings were stable and robust in the subgroup analyses. Fourth, long-term analgesic users may switch the type of analgesics they use over time. Because almost all of the studies assessed analgesics use at baseline only, we were not able to evaluate the impact of change of use of analgesics. In addition, the study does not clearly distinguish between multiple exposures to analgesics. The possibility of confounding would be especially relevant for long duration users, as those patients could have used phenacetin many years previously. Last, because of lack of data, it was not possible to address the important issues of dose and duration of use needed to achieve effects.

In summary, the results of this meta-analysis of 17 observational studies indicated that use of acetaminophen, aspirin or non-aspirin NSAIDs was not associated with bladder cancer risk. However, non-aspirin NSAIDs use might be associated with a reduction in risk of bladder cancer for nonsmokers.
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